Phenylcarboxyamides as beta-secretase inhibitors
    22.
    发明授权
    Phenylcarboxyamides as beta-secretase inhibitors 有权
    苯基羧酰胺作为β-分泌酶抑制剂

    公开(公告)号:US07476764B2

    公开(公告)日:2009-01-13

    申请号:US11494145

    申请日:2006-07-27

    Abstract: There is provided a series of novel phenylcarboxyamides of Formula (I) or a stereoisomer; or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, X and Y as defined herein, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein (APP) by β-secretase and, more specifically, inhibit the production of Aβ-peptide. The present disclosure is directed to compounds useful in the treatment of neurological disorders related to β-amyloid production, such as Alzheimer's disease and other conditions affected by anti-amyloid activity.

    Abstract translation: 提供了一系列式(I)的新型苯基羧酰胺或立体异构体; 或其药学上可接受的盐,其中如本文所定义的R 1,R 2,R 3,X和Y,其药物组合物和使用方法。 这些新型化合物通过β-分泌酶抑制淀粉样前体蛋白(APP)的加工,更具体地,抑制Aβ-肽的产生。 本公开涉及可用于治疗与β-淀粉样蛋白产生相关的神经系统疾病的化合物,例如阿尔茨海默病和受抗淀粉样蛋白活性影响的其它病症。

    Erythromycin derivatives
    24.
    发明授权
    Erythromycin derivatives 失效
    红霉素衍生物

    公开(公告)号:US06825171B2

    公开(公告)日:2004-11-30

    申请号:US10409016

    申请日:2003-04-08

    Applicant: Yong-Jin Wu

    Inventor: Yong-Jin Wu

    CPC classification number: C07H17/08

    Abstract: The invention relates to novel erythromycin derivatives, particularly ones with novel C-13 R13 substitutents, and to pharmaceutically acceptable salts thereof. The compounds of this invention are useful as antibacterial agents and antiprotozoa agents and for other applications (e.g., anticancer, atherosclerosis, gastric motility reduction, etc.) in mammals, including man, as well as in fish and. The invention also relates to pharmaceutical compositions containing such compounds and to methods of treating bacterial protozoa infections by administering such compounds. The invention also relates to methods of preparing such compounds and to intermediates useful in such preparation.

    Abstract translation: 本发明涉及新型红霉素衍生物,特别是具有新型C-13 R 13取代基的红霉素衍生物及其药学上可接受的盐。 本发明的化合物可用作抗菌剂和抗原生动物剂,以及哺乳动物,包括人以及鱼和其他用途(例如抗癌,动脉粥样硬化,胃动力降低等)。 本发明还涉及含有这些化合物的药物组合物以及通过施用这些化合物来治疗细菌原生动物感染的方法。 本发明还涉及制备此类化合物的方法和用于此类制备的中间体。

    13-methyl erythromycin derivatives
    25.
    发明授权
    13-methyl erythromycin derivatives 失效
    13-甲基红霉素衍生物

    公开(公告)号:US06777543B2

    公开(公告)日:2004-08-17

    申请号:US10441347

    申请日:2003-05-19

    CPC classification number: C07H17/08

    Abstract: The invention relates to compounds of the formula and to pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein R1, R2, R3, R4, R5, R17, Rf, A, X, and Y are as defined herein. The invention also relates to pharmaceutical compositions containing the compounds of formulas 1, methods of using the compounds of formula 1 in the treatment of infections and methods of preparing the compounds of formula 1.

    Abstract translation: 本发明涉及下式的化合物及其药学上可接受的盐,前药和溶剂化物,其中R 1,R 2,R 3,R 4,R 5,R 17,R A,X和Y如本文所定义。 本发明还涉及含有式1化合物,使用式1化合物治疗感染的方法和制备式1化合物的方法的药物组合物。

    Diaminopropane derived macrocycles as inhibitors of β amyloid production
    27.
    发明授权
    Diaminopropane derived macrocycles as inhibitors of β amyloid production 有权
    二氨基丙烷衍生的大环化合物作为抑制剂 淀粉样蛋白生成

    公开(公告)号:US07772221B2

    公开(公告)日:2010-08-10

    申请号:US12019986

    申请日:2008-01-25

    CPC classification number: C07D273/02 C07D413/04 C07D487/04

    Abstract: There is provided a series of macrocyclic diaminopropanes of Formula (I) or a stereoisomer; or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, m, n, W, X, Y, Z and L as defined herein, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein (APP) by β-secretase and, more specifically, inhibit the production of Aβ-peptide. The present disclosure is directed to compounds useful in the treatment of neurological disorders related to β-amyloid production, such as Alzheimer's disease and other conditions affected by anti-amyloid activity.

    Abstract translation: 提供一系列式(I)的大环二氨基丙烷或立体异构体; 或其药学上可接受的盐,其中如本文所定义的R 1,R 2,R 3,m,n,W,X​​,Y,Z和L,其药物组合物和使用方法。 这些新化合物通过分泌酶抑制淀粉样蛋白前体蛋白(APP)的加工,更具体地,抑制Aβ的生成。 本公开涉及可用于治疗与淀粉样蛋白产生相关的神经系统疾病的化合物,例如阿尔茨海默病和受抗淀粉样蛋白活性影响的其它病症。

    Oxime-Containing Acyl Guanidines as Beta-Secretase Inhibitors
    28.
    发明申请
    Oxime-Containing Acyl Guanidines as Beta-Secretase Inhibitors 有权
    含肟的酰基胍作为β-分泌酶抑制剂

    公开(公告)号:US20070232581A1

    公开(公告)日:2007-10-04

    申请号:US11693026

    申请日:2007-03-29

    CPC classification number: C07D209/20 C07C257/20 C07C279/22

    Abstract: There is provided a series of substituted oxime-containing acyl guanidines of Formula (I) or a stereoisomer; or a nontoxic pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, and R7 are as defined herein, their pharmaceutical compositions and methods of use. These compounds inhibit the processing of amyloid precursor protein (APP) by β-secretase and, more specifically, inhibit the production of Aβ-peptide. The present disclosure is directed to compounds useful in the treatment of neurological disorders related to β-amyloid production, such as Alzheimer's disease and other conditions affected by anti-amyloid activity.

    Abstract translation: 提供了一系列式(I)的取代的含肟基的酰基胍或立体异构体; 或其无毒的药学上可接受的盐,其中R 1,R 2,R 3,R 4,R R 5,R 6和R 7如本文所定义,其药物组合物和使用方法。 这些化合物通过β-分泌酶抑制淀粉样蛋白前体蛋白(APP)的加工,更具体地抑制Aβ-肽的产生。 本公开涉及可用于治疗与β-淀粉样蛋白产生相关的神经系统疾病的化合物,例如阿尔茨海默病和受抗淀粉样蛋白活性影响的其它病症。

    Carbamate and carbazate ketolide antibiotics
    30.
    发明授权
    Carbamate and carbazate ketolide antibiotics 失效
    氨基甲酸酯和咔唑酮酮内酯抗生素

    公开(公告)号:US06420343B1

    公开(公告)日:2002-07-16

    申请号:US09399497

    申请日:1999-09-20

    CPC classification number: C07H17/08

    Abstract: This invention relates to compounds of the formula 1 and to pharmaceutically acceptable salts, prodrugs and solvates thereof wherein X1, X2, R2 and R6 are as defined herein. The compounds of formula 1 are antibacterial and antiprotozoal agents that may be used to treat various bacterial and protozoal infections and disorders related to such infections. The invention also relates to pharmaceutical compositions containing the compounds of formula 1 and to methods of treating bacterial and protozoal infections by administering the compounds of formula 1.

    Abstract translation: 本发明涉及式1的化合物及其药学上可接受的盐,前药和溶剂合物,其中X 1,X 2,R 2和R 6如本文所定义。 式1的化合物是可用于治疗各种细菌和原生动物感染的抗细菌剂和抗原虫药,以及与这种感染有关的疾病。 本发明还涉及含有式1化合物的药物组合物和通过施用式1化合物来治疗细菌和原生动物感染的方法。

Patent Agency Ranking